Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs LYFT Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.76 (market cap $39.89B), while LYFT Inc trades at $15.8 (market cap $5.93B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.7× LYFT Inc's market cap, and LYFT Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | LYFT | |
|---|---|---|
Market Cap | $39.89B | $5.93B |
Sector | Health | Industrials |
52-Week High | $491.22 | $24.57 |
52-Week Low | $278.09 | $12.65 |
Enterprise Value | $38.15B | $5.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Lyft trades at $15.61, down 0.83% on the day, with a bullish technical signal from moving averages and key indicators like ADX. The company shows strong profitability with a net income margin of 43.82% and robust cash flow of $891M in 2025. Recent news highlights expansion into Europe and autonomous vehicle partnerships, while analyst consensus is mixed with a $18.25 price target.
Lyft presents an attractive valuation with a P/E of 2.28 and P/S of 0.99, but faces risks from competitive pressures and inconsistent earnings beats. The stock's upside potential hinges on execution of growth initiatives, though regulatory concerns and market volatility remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
